key: cord-0869805-vt05wt9q
authors: Perkmann, Thomas; Perkmann-Nagele, Nicole; Mucher, Patrick; Radakovics, Astrid; Repl, Manuela; Koller, Thomas; Jordakieva, Galateja; Wagner, Oswald F; Binder, Christoph J; Haslacher, Helmuth
title: Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
date: 2021-07-28
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.063
sha: 7d92302f7748f7cf0214bb0aa9d81158de6c5176
doc_id: 869805
cord_uid: vt05wt9q

OBJECTIVES: : Our objective was to determine whether SARS-CoV-2 antibody levels after the first dose can predict the final antibody response and whether this is dependent on the vaccine type. METHODS: : 69 BNT162b2 (Pfizer/BioNTech) and 55 AZD1222 (AstraZeneca) vaccinees without previous infection or immunosuppressive medication were included. Anti-body levels were quantified 3 weeks after dose 1, in case of AZD1222 directly before boostering (11 weeks after dose 1) and 3 weeks after dose 2, with the Roche SARS-CoV-2 S total antibody assay. RESULTS: : Pre-booster (BNT162b2: 80.6 [25.5-167.0] BAU/mL, AZD1222: 56.4 [36.4-104.8] BAU/mL, not significant) and post-booster levels (BNT162b2: 2,092.0 [1,216.3-4,431.8] BAU/mL, AZD1222: 957.0 [684.5-1,684.8] BAU/mL, p<0.0001) correlated well in BNT162b2 (ρ=0.53) but not in AZD1222 recipients. Moreover, antibody levels after the first dose of BNT162b2 correlated inversely with age (ρ=-0.33, P=0.013), whereas a positive correlation with age was observed after the second dose in AZD1222 recipients (ρ=0.26, P=0.030). CONCLUSIONS: : In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to AZ1222. In addition, we found a vaccine-dependent effect on antibody responses, where age seems to play an ambivalent role.

Methods 24 69 BNT162b2 (Pfizer/BioNTech) and 55 AZD1222 (AstraZeneca) vaccinees without previous 25 infection or immunosuppressive medication were included. Anti-body levels were quantified 3 26 weeks after dose 1, in case of AZD1222 directly before boostering (11 weeks after dose 1) and 3 27 weeks after dose 2, with the Roche SARS-CoV-2 S total antibody assay. In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 37 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to 38 AZ1222. In addition, we found a vaccine-dependent effect on antibody responses, where age 39 seems to play an ambivalent role. 40 We report here differences in the predictability of SARS-CoV-2 vaccine post-booster levels 59 measured with a quantitative antibody assay (Roche Elecsys® SARS-CoV-2 S) that depend on the 60 vaccine used. We also present the differential impact of age on the antibody response to 61 AZD1222 (AZD1222, Astra Zeneca) or BNT162b2 (BNT162b2, Pfizer/BioNTech). 62 4

Of 166 participants recruited within the MedUni Wien Biobank's healthy donors' collection until 64

March 5 th 2021, 124 were eligible for inclusion. All subjects were >18 years old and provided 65 written informed consent to participate in the study. Reasons for exclusion were a previous 66 infection with SARS-CoV-2 and ongoing immunosuppressive medication, as these conditions are 67 known to bias the average vaccination response. In addition, dropouts due to a missed blood 68 sampling and the onset of COVID between the first and second doses occurred (see Figure 1 ). 69

The prime-boost regimen specified an 11-week dosing interval for AZD1222 and a 3-week 70 dosing interval for BNT162b2. The protocol of this performance evaluation study was reviewed 71 and approved by the Ethics committee of the Medical University of Vienna (EK 1066/2021). 72

Samples were processed and, if applicable, stored before analysis at <-70°C according to BNT162b2 recipients (ρ=0.53, P<0.0001), but not for those receiving AZD1222 (ρ=0.10, P=0.393), 104 see Fig. 2A . These findings were not altered after controlling for sex in non-parametric partial 6 correlations (ρ partial =0.53, ρ partial =0.15), as this variable was differently distributed between 106

BNT162b2-and AZD1222-recipients. 107 108 Antibody levels increase steadily between 3 and 12 weeks after AZD1222 109

In the next step, the changes of SARS-CoV-2 antibody levels between 3 and 11 weeks after the 110 first AZD1222 dose were assessed. Levels were significantly higher before the booster shot Finally, we wanted to determine whether the age of the participants affected the antibody 120 responses to the two vaccines. For AZD1222, age did not correlate with the antibody levels 121 measured three weeks after dose 1 (ρ=-0.06, P=0.637) or just before dose 2 (ρ=-0.01, P=0.909). 122

However, there was a weak positive association between age and the antibody response to 123 dose 2 (ρ=0.26, P=0.030). In contrast, antibody levels assessed three weeks after the first 124 BNT162b2 dose correlated inversely with age (ρ=-0.33, P=0.013); however, this correlation was 125 mitigated after dose 2 (ρ=-0.23, P=0.093), see Our data strongly emphasize that the first dose antibody response can predict the final post-144 booster antibody levels using the mRNA vaccine BNT162b2. However, we were unable to show 145 this relationship for the vector vaccine AZD1222. To the best of our knowledge, this finding was 146 not reported before and might be explained by the specific immune response to vector 147 vaccines. In contrast to mRNA-based preparations, vector vaccines also induce an immune 148 8 response directed against the viral vector, which in the case of AZD1222 is the chimpanzee 149 adenovirus ChAdOx1 (Kaur and Gupta, 2020). De-novo anti-vector immunity could affect spike-150 protein induction and, therefore, strongly influence the association between pre-and post-151 booster values. Whether this demonstrated difference between BNT162b and AZD1222 is 152 transferable to other mRNA and vector vaccines remains to be investigated by further studies. 153

Above that, we found significant associations between antibody levels and age. With AZD1222, 154 neither of the two pre-booster samples (3 weeks and 11 weeks after dose 1) correlated with 155 age. However, after the booster shot, we found a significant positive association (ρ=0.26, 156 P=0.013), indicating that older age was associated with slightly increasing antibody levels. (2021) confirmed that older adults yield lower antibody levels after the first BNT162b2 dose, 169 with the age groups converging after the second dose.

In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 171 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to 172 AZD1222. In addition, we found a vaccine-dependent effect on antibody responses, suggesting a 173 possible link between vaccine response and vector immunity. The following conflicts of interest are to be disclosed: The Dept. of Laboratory Medicine 283 received compensations for advertisement on scientific symposia from Roche, and holds a grant 284

ethnicity, sex and prior infection status on immunogenicity following a single dose of the 195

BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers

Euro surveillance : bulletin Europeen sur les maladies 197 transmissibles =

Evaluation of 199 high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild 200 COVID-19: clinical sensitivity, specificity and association with virus neutralization test

Interim Guidelines for COVID-19 Antibody Testing in 203 Clinical and Public Health Settings

The impact of immuno-aging on SARS-CoV-2 207 vaccine development

Immunosenescence and novel vaccination strategies for the 209 elderly

European Centre for Disease Prevention and Control. The use of antibody tests for SARS-COV-2 211 in the context of Digital Green Certificates-20

Quantitative SARS-CoV-2 anti-spike 213 responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

Microbiol Infect

The conundrum of current anti-SARS-CoV-2 vaccines

Correlates of protection against 218 symptomatic and asymptomatic SARS-CoV-2 infection

SARS-CoV-2 infection rates of 220 antibody-positive compared with antibody-negative health-care workers in England: a large

multicentre, prospective cohort study (SIREN)

Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based 224

COVID-19 Vaccine: A comprehensive status report

Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

WHO International 231 Standard for anti-SARS-CoV-2 immunoglobulin

Antibody Status 233 and Incidence of SARS-CoV-2 Infection in Health Care Workers

BNT162b2 COVID-19 vaccine 236 and correlates of humoral immune responses and dynamics: a prospective, single-centre, 237 longitudinal cohort study in health-care workers. The Lancet Respiratory Medicine

Age-dependent 239 immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid 242

Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on 245

Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of 248

Serum 250 antibody response to BNT162b2 after natural SARS-CoV-2 infection

Robust antibody 253 responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-254 19 vaccine

Population 256 homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only 257 reached after the second dose, across all adult age ranges

The initial 259 impact of a national BNT162b2 mRNA COVID-19 vaccine rollout